Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of JNJ-78934804 versus guselkumab in moderate to severe active Crohn's disease
MOH_2026-05-19_015834Phase 3Recruiting
- Sponsor
- Janssen Research & Development
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of guselkumab and golimumab in Crohn's disease (2 arms), sponsored by Janssen Research & Development. Primary endpoint: Efficacy of JNJ-78934804 compared with guselkumab at week 48. Started May 2026; status: recruiting.
02
Drugs
guselkumabgolimumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on MOH_2026-05-19_015834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-05-19_015834.